Wow, thanks so much for this comprehensive overview of the treatment (and prevention) landscape, this is so helpful! A lot of food for thought for someone early 50s with one APOE4 allele and some family history...seeing all that is in the pipeline and what we are learning makes me cautiously optimistic. :)
It's so useful to have an overview the approaches and clinical trials, as things have changed significantly in recent years. Something I see from time to time is the claim that there are individuals who were cognitively healthy upon death, yet an autopsy revealed accumulation of amyloid plaques, meaning some people have amyloid plaques but do not show Alzheimer's disease. Is this true, and what would it mean?
(A small note: there seems to be a typo in the sentence, "AR1001 (mirodenafil) warrants attention because it is not an oral daily pill, not an IV infusion requiring clinic visits and MRI monitoring." The first "not" should be deleted unless I misunderstand something.)
Hi Jay! This is absolutely true. There are many people with amyloid plaques with no memory problems. Amyloid is one risk factor amongst many for Alzheimer's and is not sufficient to cause the disease. This is the same thing as high cholesterol is not the only risk factor for heart disease. This is why we need to understand what is driving each person's Alzheimer's and match them to the correct therapeutic approach.
This is a very clear articulation of something the field has taken too long to absorb: many apparent treatment failures in Alzheimer’s were not necessarily failures of mechanism, but failures of timing.
From a clinical perspective, that distinction matters a great deal. By the time the disease becomes symptomatically obvious, the underlying biology has often been active for years, sometimes decades, and the downstream damage may already have its own momentum. In that setting, modest effect sizes may say less about whether the biology is real than about whether the intervention arrived too late.
What I found especially important in your piece is the shift in the question itself, away from “Does this drug work?” in the abstract, and toward “In whom, against which biology, and at what stage?” That strikes me as a much more faithful way to think about the pipeline now, and probably the question on which real progress will depend.
The compelling instances of individuals exhibiting substantial amyloid plaques without cognitive impairment speak directly to the dynamic complexity of Alzheimer's and the transformative direction of the field. This biological divergence signals that while amyloid is a significant risk factor, its presence alone does not dictate clinical manifestation. It highlights the profound influence of other upstream processes, such as neuroinflammation or the overarching program of brain aging, in determining symptomatic onset. This understanding is precisely what drives the imperative for patient selection models and the development of multi-modal biomarker assessments, moving us toward a future where we can delineate specific biological subtypes. Our goal is to empower proactive health strategies by identifying an individual's unique neurobiological profile, ensuring that emerging therapies, including advanced epigenetic reprogramming and targeted therapeutics, are applied with maximum precision at the earliest, most impactful stages.
Wow, thanks so much for this comprehensive overview of the treatment (and prevention) landscape, this is so helpful! A lot of food for thought for someone early 50s with one APOE4 allele and some family history...seeing all that is in the pipeline and what we are learning makes me cautiously optimistic. :)
It's so useful to have an overview the approaches and clinical trials, as things have changed significantly in recent years. Something I see from time to time is the claim that there are individuals who were cognitively healthy upon death, yet an autopsy revealed accumulation of amyloid plaques, meaning some people have amyloid plaques but do not show Alzheimer's disease. Is this true, and what would it mean?
(A small note: there seems to be a typo in the sentence, "AR1001 (mirodenafil) warrants attention because it is not an oral daily pill, not an IV infusion requiring clinic visits and MRI monitoring." The first "not" should be deleted unless I misunderstand something.)
Hi Jay! This is absolutely true. There are many people with amyloid plaques with no memory problems. Amyloid is one risk factor amongst many for Alzheimer's and is not sufficient to cause the disease. This is the same thing as high cholesterol is not the only risk factor for heart disease. This is why we need to understand what is driving each person's Alzheimer's and match them to the correct therapeutic approach.
Thanks for pointing out the typo- correcting now
This is a very clear articulation of something the field has taken too long to absorb: many apparent treatment failures in Alzheimer’s were not necessarily failures of mechanism, but failures of timing.
From a clinical perspective, that distinction matters a great deal. By the time the disease becomes symptomatically obvious, the underlying biology has often been active for years, sometimes decades, and the downstream damage may already have its own momentum. In that setting, modest effect sizes may say less about whether the biology is real than about whether the intervention arrived too late.
What I found especially important in your piece is the shift in the question itself, away from “Does this drug work?” in the abstract, and toward “In whom, against which biology, and at what stage?” That strikes me as a much more faithful way to think about the pipeline now, and probably the question on which real progress will depend.
The compelling instances of individuals exhibiting substantial amyloid plaques without cognitive impairment speak directly to the dynamic complexity of Alzheimer's and the transformative direction of the field. This biological divergence signals that while amyloid is a significant risk factor, its presence alone does not dictate clinical manifestation. It highlights the profound influence of other upstream processes, such as neuroinflammation or the overarching program of brain aging, in determining symptomatic onset. This understanding is precisely what drives the imperative for patient selection models and the development of multi-modal biomarker assessments, moving us toward a future where we can delineate specific biological subtypes. Our goal is to empower proactive health strategies by identifying an individual's unique neurobiological profile, ensuring that emerging therapies, including advanced epigenetic reprogramming and targeted therapeutics, are applied with maximum precision at the earliest, most impactful stages.